研究業績 2016年

  • Miyata H, Takada T, Toyoda Y, Matsuo H, Ichida K, Suzuki H. Identification of febuxostat as a new strong ABCG2 inhibitor: potential applications and risks in clinical situations. Front Pharmacol. 2016 7:518. [open access]
  • Tomioka NH, Tamura Y, Takada T, Shibata S, Suzuki H, Uchida S, Hosoyamada M. Immunohistochemical and in situ hybridization study of urate transporters GLUT9/URATv1, ABCG2, and URAT1 in the murine brain. Fluids Barriers CNS. 2016 13(1):22. [abstract]
  • Higashino T, Matsuo H, Sakiyama M, Nakayama A, Nakamura T, Takada T, Ogata H, Kawamura Y, Kawaguchi M, Naito M, Kawai S, Takada Y, Ooyama H, Suzuki H, Shinomiya N. Common variant of PDZ domain containing 1 (PDZK1) gene is associated with gout susceptibility: A replication study and meta-analysis in Japanese population. Drug Metab Pharmacokinet. 2016 31(6):464-466. [abstract]
  • Matsuo H, Tsunoda T, Ooyama K, Sakiyama M, Sogo T, Takada T, Nakashima A, Nakayama A, Kawaguchi M, Higashino T, Wakai K, Ooyama H, Hokari R, Suzuki H, Ichida K, Inui A, Fujimori S, Shinomiya N. Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2. Sci Rep. 2016 6:31003. [abstract]
  • Sugamori Y, Mise-Omata S, Maeda C, Aoki S, Tabata Y, Murali R, Yasuda H, Udagawa N, Suzuki H, Honma M, Aoki K. Peptide drugs accelerate BMP-2-induced calvarial bone regeneration and stimulate osteoblast differentiation through mTORC1 signaling. Bioessays 2016 38(8):717-25. [abstract]
  • Toyoda Y, Takada T, Miyata H, Ishikawa T, Suzuki H. Regulation of the Axillary Osmidrosis-Associated ABCC11 Protein Stability by N-Linked Glycosylation: Effect of Glucose Condition. PLoS ONE 2016 11(6):e0157172. [open access]
  • Toyoda Y, Takada T, Suzuki H. Halogenated hydrocarbon solvent-related cholangiocarcinoma risk: biliary excretion of glutathione conjugates of 1,2-dichloropropane evidenced by untargeted metabolomics analysis. Sci Rep. 2016 6:24586. [open access] [プレスリリース] [UTokyo Research（和文解説）] [東大病院だより No.88（研究紹介）]
  • Matsuo H, Yamamoto K, Nakaoka H, Nakayama A, Sakiyama M, Chiba T, Takahashi A, Nakamura T, Nakashima H, Takada Y, Danjoh I, Shimizu S, Abe J, Kawamura Y, Terashige S, Ogata H, Tatsukawa S, Yin G, Okada R, Morita E, Naito M, Tokumasu A, Onoue H, Iwaya K, Ito T, Takada T, Inoue K, Kato Y, Nakamura Y, Sakurai Y, Suzuki H, Kanai Y, Hosoya T, Hamajima N, Inoue I, Kubo M, Ichida K, Ooyama H, Shimizu T, Shinomiya N. 　Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. 　Ann Rheum Dis. 2016 75(4):652-659. [abstract] [プレスリリース] 
  • Sakiyama M, Matsuo H, Shimizu S, Nakashima H, Nakamura T, Nakayama A, Higashino T, Naito M, Suma S, Hishida A, Satoh T, Sakurai Y, Takada T, Ichida K, Ooyama H, Shimizu T, Shinomiya N. The effects of URAT1/SLC22A12 nonfunctional variants,R90H and W258X, on serum uric acid levels and gout/hyperuricemia progression.  Sci Rep. 2016 6:20148. [abstract]
  • Stiburkova B, Miyata H, Zavada J, Tomcik M, Pavelka K, Storkanova G, Toyoda Y, Takada T, Suzuki H. Novel dysfunctional variant in ABCG2 as a cause of severe tophaceous gout:biochemical, molecular genetic and functional analysis. Rheumatology 2016 55(1):191-194. [abstract]